ArticleFrontiers in pharmacology2017
Scaffold Diversity of Fungal Metabolites.
Article in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- sCentInDB: a database of essential oil chemical profiles of Indian medicinal plants.Molecular diversity · 2026Article
- XAI-ACSM: An Ensemble-Based Explainable Artificial Intelligence Framework for the Accurate Prediction of Anticancer Small Molecules.ACS omega · 2025Article
- Harnessing Molecular and Bioactivity Network Analysis to Prioritize Antibacterial Compound Isolation From Ant-Associated Fungi.Phytochemical analysis : PCA · 2025Article
- Verticillins: fungal epipolythiodioxopiperazine alkaloids with chemotherapeutic potential.Natural product reports · 2024Review
- Navigating the Chemical Space of ENR Inhibitors: A Comprehensive Analysis.Antibiotics (Basel, Switzerland) · 2024Article
- Predicting fungal secondary metabolite activity from biosynthetic gene cluster data using machine learning.Microbiology spectrum · 2024Article
- Sheptide A: an antimalarial cyclic pentapeptide from a fungal strain in the Herpotrichiellaceae.The Journal of antibiotics · 2023Article
- IMPPAT 2.0: An Enhanced and Expanded Phytochemical Atlas of Indian Medicinal Plants.ACS omega · 2023Article
- Scaffold and Structural Diversity of the Secondary Metabolite Space of Medicinal Fungi.ACS omega · 2023Article
- Discovery of Anticancer Agents of Diverse Natural Origin.Journal of natural products · 2022Article
- Biosynthesis of Fungal Natural Products Involving Two Separate Pathway Crosstalk.Journal of fungi (Basel, Switzerland) · 2022Review
- Polyketides isolated from an endophyteFrontiers in microbiology · 2022Article
- Comprehensive Survey of Recent Drug Discovery Using Deep Learning.International journal of molecular sciences · 2021Review
- Three diketomorpholines from a Penicillium sp. (strain G1071).Phytochemistry · 2021Article
- Latin American databases of natural products: biodiversity and drug discovery against SARS-CoV-2.RSC advances · 2021Article
- Opportunities and Limitations for Assigning Relative Configurations of Antibacterial Bislactones using GIAO NMR Shift Calculations.Journal of natural products · 2021Article
- Cytotoxic Naphthoquinone Analogues, Including Heterodimers, and Their Structure Elucidation Using LR-HSQMBC NMR Experiments.Journal of natural products · 2021Article
- MeFSAT: a curated natural product database specific to secondary metabolites of medicinal fungi.RSC advances · 2021Article
- New Polyketides With Anti-Inflammatory Activity From the FungusFrontiers in pharmacology · 2021Article
- Cheminformatics in Natural Product-based Drug Discovery.Molecular informatics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Many drug discovery projects rely on commercial compounds to discover active leads. However, current commercial libraries, with mostly synthetic compounds, access a small fraction of the possible chemical diversity. Natural products, in contrast, possess a vast structural diversity and have proven to be an outstanding source of new drugs. Several chemoinformatic analyses of natural products have demonstrated their diversity and structural complexity. However, to our knowledge, the scaffold content and structural diversity of fungal secondary metabolites have never been studied. Herein, the scaffold diversity of 223 fungal metabolites was measured and compared to the diversity of approved drugs and commercial libraries for HTS containing natural, synthetic, and semi-synthetic compounds. In addition, the global diversity of the fungal isolates was assessed and compared to other reference data sets using Consensus Diversity Plots, a chemoinformatic tool recently developed. It was concluded that fungal secondary metabolites are cyclic systems with few ramifications and more diverse than the commercial libraries with natural products and semi-synthetic compounds. The fungal metabolites data set was one of the most structurally diverse, containing a large proportion of different and unique scaffolds not found in the other compound data sets including ChEMBL. Therefore, fungal metabolites offer a rich source of molecules suited for identifying diverse candidates for drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.